RegentAtlantic Capital
MTNB icon

RegentAtlantic Capital’s Matinas BioPharma MTNB Stock Holding History

RegentAtlantic Capital’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20
Closed -$16K – 638
2021
Q1 		$16K Sell
20
-7
-26% -$7.04K ﹤0.01% 547
2020
Q4 		$27K Hold
27
– – ﹤0.01% 498
2020
Q3 		$15K Hold
27
– – ﹤0.01% 490
2020
Q2 		$15K Hold
27
– – ﹤0.01% 474
2020
Q1 		$12K Hold
27
– – ﹤0.01% 413
2019
Q4 		$45K Buy
+27
New +$23.5K ﹤0.01% 459

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $67.3M AUM 9.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

RegentAtlantic Capital's MTNB Position: Q2 2021 in Review

RegentAtlantic Capital sold out of Matinas BioPharma (MTNB) in Q2 2021, closing a stake of 20 shares — an estimated $16K sold.

RegentAtlantic Capital first reported a position in MTNB in Q4 2019 and held it in 6 quarters. The position peaked at $45K in Q4 2019. 66 funds tracked by Wall St. Rank hold MTNB as of Q2 2021.

  • RegentAtlantic Capital reported no remaining Matinas BioPharma position as of Q2 2021 after selling out during the quarter.
  • RegentAtlantic Capital sold 20 Matinas BioPharma shares in Q2 2021, an estimated $16K.
  • RegentAtlantic Capital first reported a position in Matinas BioPharma in Q4 2019 and held it in 6 quarters.
  • RegentAtlantic Capital's Matinas BioPharma position peaked at $45K in Q4 2019.
  • 66 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2021.

Based on RegentAtlantic Capital's 13F filing for Q2 2021, filed 12 Aug 2021.